- Home
- ATER vs KPRX Comparison
ATER vs KPRX Comparison
Compare ATER & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- KPRX
- Stock Information
- Founded
- ATER 2014
- KPRX 1998
- Country
- ATER United States
- KPRX United States
- Employees
- ATER N/A
- KPRX N/A
- Industry
- ATER Home Furnishings
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATER Consumer Discretionary
- KPRX Health Care
- Exchange
- ATER Nasdaq
- KPRX Nasdaq
- Market Cap
- ATER 10.3M
- KPRX 9.2M
- IPO Year
- ATER N/A
- KPRX N/A
- Fundamental
- Price
- ATER $1.07
- KPRX N/A
- Analyst Decision
- ATER
- KPRX Strong Buy
- Analyst Count
- ATER 0
- KPRX 1
- Target Price
- ATER N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ATER 130.3K
- KPRX 45.2K
- Earning Date
- ATER 11-10-2025
- KPRX 11-07-2025
- Dividend Yield
- ATER N/A
- KPRX N/A
- EPS Growth
- ATER N/A
- KPRX N/A
- EPS
- ATER N/A
- KPRX N/A
- Revenue
- ATER $85,668,000.00
- KPRX N/A
- Revenue This Year
- ATER N/A
- KPRX N/A
- Revenue Next Year
- ATER $7.48
- KPRX N/A
- P/E Ratio
- ATER N/A
- KPRX N/A
- Revenue Growth
- ATER N/A
- KPRX N/A
- 52 Week Low
- ATER $0.90
- KPRX $2.25
- 52 Week High
- ATER $3.50
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- ATER 48.70
- KPRX 51.13
- Support Level
- ATER $1.04
- KPRX $2.65
- Resistance Level
- ATER $1.12
- KPRX $2.85
- Average True Range (ATR)
- ATER 0.08
- KPRX 0.14
- MACD
- ATER -0.00
- KPRX 0.00
- Stochastic Oscillator
- ATER 20.00
- KPRX 44.88
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.